Abstract 3050
Background
Although surgical resection is the main treatment for rectal cancer, the optimal surgical protocol for elderly patients with rectal cancer remains controversial. Robot-assisted surgery has the following advantages: smaller wounds, less blood loss, quicker recovery, early recovery, and high rate of anal preservation. This study evaluated the feasibility of robot-assisted surgery in elderly patients with rectal cancer.
Methods
This retrospective study enrolled 125 patients aged 28–93 years diagnosed with stage I–III rectal cancer who underwent robot-assisted surgery between May 2013 and April 2018 in a single institution.
Results
In total, 125 patients with rectal cancer, including 100 nonelderly (aged <70 years) and 25 elderly (aged ≥70 years) patients, who underwent robot-assisted surgery were recruited. Between the patient groups, the incidence of overall postoperative complications and postoperative length of hospital stay did not differ significantly (p = 0.930 and 0.095, respectively). No surgical related deaths were noted. The disease-free and overall survival did not differ significantly between the 2 groups (p = 0.610 and 0.298, respectively).
Conclusions
Robot-assisted surgery for rectal cancer is an appropriate approach that is well tolerated in elderly patients, with similar results as for the non-elderly patients. Oncological outcomes, including postoperative complications and survival, did not depend on patient age. Thus, in elderly patients, robot-assisted surgery is a safe and feasible surgical modality for treating operable rectal cancer and leads to age-independent postoperative outcomes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Wei-Chih Su.
Funding
Kaohsiung Medical University Hospital.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2551 - Efficacy of dose-dense (DD) adjuvant chemotherapy (CT) in hormone receptor positive/HER2-negative early breast cancer (BC) patients (pts) according to immunohistochemically (IHC) defined luminal subtypes: an exploratory analysis of the GIM2 trial.
Presenter: Benedetta Conte
Session: Poster Display session 2
Resources:
Abstract
3426 - High dose Neo-adjuvant chemotherapy in Triple-Negative breast cancer with evidence of homologous recombination deficiency (HRD).
Presenter: Sonja Vliek
Session: Poster Display session 2
Resources:
Abstract
3792 - Risk factors for locoregional recurrence (LRR) after neoadjuvant chemotherapy: pooled analysis of prospective neoadjuvant breast cancer (BC) trials
Presenter: Gustavo Werutsky
Session: Poster Display session 2
Resources:
Abstract
4044 - Estimating radiotherapy-induced cardiovascular mortality in female breast cancer patients.
Presenter: Mark De Ridder
Session: Poster Display session 2
Resources:
Abstract
719 - 3-year follow-up of a phase III trial comparing the efficacy and safety of neoadjuvant and adjuvant trastuzumab and its biosimilar CT-P6 in HER2 positive early breast cancer (EBC)
Presenter: Justin Stebbing
Session: Poster Display session 2
Resources:
Abstract
3595 - Adjuvant chemotherapy in elderly breast cancer patients: pattern of use and impact on overall survival
Presenter: Axel Berthelot
Session: Poster Display session 2
Resources:
Abstract
3992 - Carboplatin-containing neoadjuvant chemotherapy for triple negative breast cancer (TNBC): a propensity score-matched study.
Presenter: Maria Vittoria Dieci
Session: Poster Display session 2
Resources:
Abstract
3477 - Impact of adjuvant trastuzumab emtansine (T-DM1) on incidence of metastatic breast cancer (mBC): an epidemiological model of patients with HER2-positive breast cancer (BC) who did not achieve pathological complete response (pCR) after neoadjuvant treatment (non-pCR)
Presenter: Mellissa Williamson
Session: Poster Display session 2
Resources:
Abstract
3928 - Chemotherapy (CT)-induced anaemia in patients (pts) treated with dose-dense regimen: Results of the prospectively randomised anaemia substudy from the neoadjuvant GeparOcto study
Presenter: Hans Tesch
Session: Poster Display session 2
Resources:
Abstract
2184 - The clinical impact of adjuvant dose-dense sequential chemotherapy (dds-CT) in patients with high-risk operable breast cancer (BC); pooled analysis of 6 clinical trials.
Presenter: Elena Fountzilas
Session: Poster Display session 2
Resources:
Abstract